Download PDF
Semin Respir Crit Care Med 2013; 34(06): 802-809
DOI: 10.1055/s-0033-1358560
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Treatment of Lung Cancer in the Elderly Patient

Jared Weiss
1   Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
,
Corey Langer
1   Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
› Author Affiliations
Further Information

Publication History

Publication Date:
20 November 2013 (online)

    Permissions and Reprints

Abstract

The median age of presentation with lung cancer is 71, making the elderly the dominant subgroup. Although some elderly patients are frail, others have great physiological reserve. Geriatric assessment can clarify the specific strengths and weaknesses of older patients, improving management. This assessment should, at the minimum, encompass performance status, comorbidity, medications, level of independence in activities of daily living and instrumental activities of daily living, cognitive assessment, nutrition assessment, and assessment of social support. The fit elderly with localized disease should be offered curative resection; video-assisted thoracic surgery may be preferred over thoracotomy. Fit septuagenarians with node positive or > 4 cm primary tumors should then be considered for adjuvant chemotherapy. For less fit patients, the data on stereotactic radiosurgery indicate that it presents a viable treatment option. Data on stage III disease are limited but suggest that chemoradiotherapy, particularly when the chemotherapy is administered on a weekly schedule, is feasible in fit older patients. For the older patients with metastatic cancer, abundant tissue should be obtained at diagnosis to allow for comprehensive molecular characterization with the hopes of rendering the patient eligible for targeted therapy. When such a targeted therapy is not available, there is duration of life and quality of life benefit to the administration of cytotoxic chemotherapy. The standard of care for older patients with Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 is a platinum-based doublet. Prospective data on second-line therapy after failure of first-line therapy are limited but suggest a benefit to treatment.

Keywords

elderly - geriatric - geriatric assessment
 

  • References

  • 1 Howlader N, Noone A, Krapcho M , et al. SEER Cancer Statistics Review, 1975–2008. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2008/ . Based on November 2010 SEER data submission, posted to the SEER web site, Accessed June 1, 2013
    PubMed
  • 2 Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40 (5) 373-383
    CrossrefPubMedGoogle Scholar
  • 3 Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16 (4) 1582-1587
    PubMedGoogle Scholar
  • 4 Performance Status ECOG. ecog.dfci.harvard.edu/general/perf_stat.html . Accessed June 1, 2013
    PubMed
  • 5 Karnofsky DABJ. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, , ed. Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949: 196
    Google Scholar
  • 6 Johansen J, Boisen MK, Mellemgaard A, Holm B. Prognostic value of ECOG performance status in lung cancer assessed by patients and physicians [abstract]. J Clin Oncol 2013; 31 (Suppl; abstr 8103)
    PubMedGoogle Scholar
  • 7 Firat S, Byhardt RW, Gore E ; Radiation Therapy Oncology Group. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Int J Radiat Oncol Biol Phys 2002; 54 (2) 357-364
    CrossrefPubMedGoogle Scholar
  • 8 Janssen-Heijnen ML, Schipper RM, Razenberg PP, Crommelin MA, Coebergh JW. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 1998; 21 (2) 105-113
    CrossrefPubMedGoogle Scholar
  • 9 Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007; 25 (14) 1824-1831
    CrossrefPubMedGoogle Scholar
  • 10 Maione P, Perrone F, Gallo C , et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 2005; 23 (28) 6865-6872
    CrossrefPubMedGoogle Scholar
  • 11 Stuck AE, Siu AL, Wieland GD, Adams J, Rubenstein LZ. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 1993; 342 (8878) 1032-1036
    CrossrefPubMedGoogle Scholar
  • 12 Balducci L. The geriatric cancer patient: equal benefit from equal treatment. Cancer Contr 2001; 8 (2, Suppl): 1-25 , quiz 27–28
    PubMedGoogle Scholar
  • 13 Hurria A, Gupta S, Zauderer M , et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 2005; 104 (9) 1998-2005
    CrossrefPubMedGoogle Scholar
  • 14 Hurria AMH, Cohen HJ. Cancer and aging. In: Kufe DW, Holland JF, Frei E, , eds. Holland Frei Cancer Medicine. Hamilton, ON: Decker; 2006: 949-958
    Google Scholar
  • 15 Muss HB, Hunter CP, Johnson KA. Treatment and Management of Cancer in the Elderly. New York: Informa (Taylor & Francis); 2006
    Google Scholar
  • 16 Mery CM, Pappas AN, Bueno R , et al. Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database. Chest 2005; 128: 237-245
    CrossrefPubMedGoogle Scholar
  • 17 Ginsberg RJ, Hill LD, Eagan RT , et al. Modern thirty-day operative mortality for surgical resections in lung cancer. J Thorac Cardiovasc Surg 1983; 86: 654-658
    CrossrefPubMedGoogle Scholar
  • 18 Mun M, Kohno T. Video-assisted thoracic surgery for clinical stage i lung cancer in octogenarians. Ann Thorac Surg 2008; 85: 406-411
    CrossrefPubMedGoogle Scholar
  • 19 Wada H, Nakamura T, Nakamoto K , et al. Thirty-day operative mortality for thoracotomy in lung cancer. J Thorac Cardiovasc Surg 1998; 115: 70-73
    CrossrefPubMedGoogle Scholar
  • 20 Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for t1 n0 non-small cell lung cancer. Lung cancer study group. Ann Thorac Surg 1995; 60: 615-622 ; discussion 622–613
    CrossrefPubMedGoogle Scholar
  • 21 Flores RM, Park BJ, Dycoco J , et al. Lobectomy by video-assisted thoracic surgery (vats) versus thoracotomy for lung cancer. J Thorac Cardiovasc Surg 2009; 138: 11-18
    CrossrefPubMedGoogle Scholar
  • 22 McKenna Jr. RJ, Houck W, Fuller CB. Video-assisted thoracic surgery lobectomy: Experience with 1,100 cases. Ann Thorac Surg 2006; 81: 421-425 ; discussion 425–426
    CrossrefPubMedGoogle Scholar
  • 23 Swanson SJ, Herndon 2nd JE, D'Amico TA , et al. Video-assisted thoracic surgery lobectomy: Report of calgb 39802–a prospective, multi-institution feasibility study. J Clin Oncol 2007; 25: 4993-4997
    CrossrefPubMedGoogle Scholar
  • 24 Koren JP, Bocage JP, Geis WP , et al. Major thoracic surgery in octogenarians: The video-assisted thoracic surgery (vats) approach. Surg Endosc 2003; 17: 632-635
    CrossrefPubMedGoogle Scholar
  • 25 Jaklitsch MT, DeCamp Jr MM, Liptay MJ , et al. Video-assisted thoracic surgery in the elderly. A review of 307 cases. Chest 1996; 110 (3) 751-758
    CrossrefPubMedGoogle Scholar
  • 26 Non-small Cell Lung Cancer Collaborative Group. Chemotherapy for non-small cell lung cancer. Cochrane Database of Systematic Reviews 2000; (2) CD002139 doi:101002/14651858CD002139
    PubMedGoogle Scholar
  • 27 Pignon JP, Tribodet H, Scagliotti GV , et al; LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26 (21) 3552-3559
    CrossrefPubMedGoogle Scholar
  • 28 National Comprehensive Cancer Network. Non-Small Cell Lung Cancer Version 2. 2013 www.nccn.org Accessed February 10, 2013
    PubMedGoogle Scholar
  • 29 Wisnivesky JP, Smith CB, Packer S , et al. Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study. BMJ 2011; 343: d4013
    CrossrefPubMedGoogle Scholar
  • 30 Winton T, Livingston R, Johnson D , et al; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352 (25) 2589-2597
    CrossrefPubMedGoogle Scholar
  • 31 Pepe C, Hasan B, Winton TL , et al; National Cancer Institute of Canada and Intergroup Study JBR.10. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 2007; 25 (12) 1553-1561
    CrossrefPubMedGoogle Scholar
  • 32 Früh M, Rolland E, Pignon JP , et al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol 2008; 26 (21) 3573-3581
    CrossrefPubMedGoogle Scholar
  • 33 Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review. Thorax 2001; 56 (8) 628-638
    CrossrefPubMedGoogle Scholar
  • 34 Timmerman R, Paulus R, Galvin J , et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303 (11) 1070-1076
    CrossrefPubMedGoogle Scholar
  • 35 Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol 2012; 13 (8) 802-809
    CrossrefPubMedGoogle Scholar
  • 36 Haasbeek CJ, Lagerwaard FJ, Antonisse ME, Slotman BJ, Senan S. Stage I nonsmall cell lung cancer in patients aged > or = 75 years: outcomes after stereotactic radiotherapy. Cancer 2010; 116 (2) 406-414
    CrossrefPubMedGoogle Scholar
  • 37 Samuels MA, Kandula S, Koru-Sengul T , et al. Stereotactic body radiotherapy in patients with stage I non-small-cell lung cancer aged 75 years and older: retrospective results from a multicenter consortium. Clin Lung Cancer 2013; 14 (4) 446-451
    CrossrefPubMedGoogle Scholar
  • 38 van der Voort van Zyp NC, van der Holt B, van Klaveren RJ, Pattynama P, Maat A, Nuyttens JJ. Stereotactic body radiotherapy using real-time tumor tracking in octogenarians with non-small cell lung cancer. Lung Cancer 2010; 69 (3) 296-301
    CrossrefPubMedGoogle Scholar
  • 39 Weiss J, Langer C. NSCLC in the elderly—the legacy of therapeutic neglect. Curr Treat Options Oncol 2009; 10 (3-4) 180-194
    CrossrefPubMedGoogle Scholar
  • 40 Atagi S, Kawahara M, Yokoyama A , et al; Japan Clinical Oncology Group Lung Cancer Study Group. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 2012; 13 (7) 671-678
    CrossrefPubMedGoogle Scholar
  • 41 Shaw AT, Yeap BY, Mino-Kenudson M , et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27 (26) 4247-4253
    CrossrefPubMedGoogle Scholar
  • 42 Fukuoka M, Wu YL, Thongprasert S , et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29 (21) 2866-2874
    CrossrefPubMedGoogle Scholar
  • 43 Maemondo M, Inoue A, Kobayashi K , et al; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362 (25) 2380-2388
    CrossrefPubMedGoogle Scholar
  • 44 Mitsudomi T, Morita S, Yatabe Y , et al; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11 (2) 121-128
    CrossrefPubMedGoogle Scholar
  • 45 Rosell R, Carcereny E, Gervais R , et al; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13 (3) 239-246
    CrossrefPubMedGoogle Scholar
  • 46 Zhou C, Wu YL, Chen G , et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12 (8) 735-742
    CrossrefPubMedGoogle Scholar
  • 47 Shaw AT, Kim DW, Nakagawa K , et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368 (25) 2385-2394
    CrossrefPubMedGoogle Scholar
  • 48 Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 2001; 6 (Suppl. 01) 4-7
    PubMedGoogle Scholar
  • 49 Quoix E, Zalcman G, Oster JP , et al; Intergroupe Francophone de Cancérologie Thoracique. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011; 378 (9796) 1079-1088
    CrossrefPubMedGoogle Scholar
  • 50 Zukin M, Barrios CH, Rodrigues Pereira J , et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol 2013; 31 (23) 2849-2853
    CrossrefPubMedGoogle Scholar
  • 51 Weiss GJ, Langer C, Rosell R , et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006; 24 (27) 4405-4411
    CrossrefPubMedGoogle Scholar
  • 52 Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26 (14) 2350-2357
    CrossrefPubMedGoogle Scholar
  • 53 Lazzari C, Novello S, Barni S , et al. Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE) [abstract]. J Clin Oncol 2013; ;31(Suppl; abstr LBA8005)
    PubMedGoogle Scholar
  • 54 Social Security Administration. Actuarial Life Table SSA. www.ssa.gov/oact/STATS/table4c6.html . Accessed June 1, 2013
    PubMedGoogle Scholar